|
Market Closed -
Nasdaq
16:00:00 2026-10-30 EDT
|
5-day change | 1st Jan Change | ||
| 2.570 USD | -4.81% |
|
-7.22% | +80.99% |
| 10-15 | Edesa Biotech, Inc. Receives FDA IND Clearance For Phase 2 Clinical Study Of EB06 In Vitiligo | CI |
| 08-19 | Edesa Biotech Launches Public Offering of Common Shares, Warrants | MT |
Company Valuation: Edesa Biotech, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: September | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 97.83 | 14.25 | 13.33 | 14.45 | 17.38 | 34.72 | - | - |
| Change | - | -85.44% | -6.42% | 8.4% | 20.29% | 99.76% | - | - |
| Enterprise Value (EV) | 97.83 | 14.25 | 13.33 | 14.45 | 17.38 | 34.72 | 34.72 | 34.72 |
| Change | - | -85.44% | -6.42% | 8.4% | 20.29% | 99.76% | 0% | 0% |
| P/E | -6.71x | -0.88x | -1.51x | -2.31x | -1.94x | -1.29x | -1.24x | -1.25x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | 0.19x | 0x | 0.1x | 0.1x | -0x | -0.31x | 1.55x |
| Capitalization / Revenue | - | - | - | - | - | - | - | 1.49x |
| EV / Revenue | - | - | - | - | - | - | - | 1.49x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / EBIT | -0x | -0x | -0x | -0x | -0x | -1.94x | -1.44x | -1.06x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -7.7 | -7.35 | -2.93 | -1.93 | -1.27 | -1.987 | -2.067 | -2.05 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | - | - | - | - | - | - | - | 23.26 |
| EBITDA | -23.56 | - | - | - | - | - | - | - |
| EBIT 1 | -23.68 | -18.37 | -9.223 | -7.015 | -7.912 | -17.93 | -24.13 | -32.89 |
| Net income 1 | -13.34 | -17.55 | -8.374 | -6.17 | -7.186 | -17.52 | -23.88 | -32.64 |
| Net Debt | - | - | - | - | - | - | - | - |
| Reference price 2 | 51.660 | 6.449 | 4.424 | 4.450 | 2.470 | 2.570 | 2.570 | 2.570 |
| Nbr of stocks (in thousands) | 1,894 | 2,209 | 3,013 | 3,247 | 7,038 | 13,512 | - | - |
| Announcement Date | 12/28/21 | 12/16/22 | 12/15/23 | 12/13/24 | 12/12/25 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.29x | - | - | - | 34.72M | |
| 16.87x | 6.34x | 12.15x | 1.77% | 63.77B | |
| 30.14x | 8.25x | 27.02x | 0.04% | 56.37B | |
| 37.48x | 6.65x | 19.85x | 0.86% | 54.62B | |
| 34.93x | 3.32x | 14.34x | -.--% | 44.06B | |
| 48.85x | 5.63x | 30.81x | -.--% | 42.11B | |
| -19.86x | 192.36x | -21.16x | -.--% | 41B | |
| 47.33x | 8.41x | 28.18x | -.--% | 34.92B | |
| 32x | 8.13x | 21.15x | 0.41% | 32.82B | |
| -64.56x | 13.05x | -73.23x | -.--% | 24.7B | |
| Average | 16.19x | 28.02x | 6.57x | 0.34% | 39.44B | |
| Weighted average by Cap. | 22.09x | 26.34x | 10.94x | 0.45% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- EDSA Stock
- Valuation Edesa Biotech, Inc.
Select your edition
All financial news and data tailored to specific country editions
